Novel lilrb2 antibodies and uses thereof
AssigneesBoard of Regents, The University of Texas System, Immune-Onc Therapeutics, Inc.
InventorsZhiqiang AN, Ningyan ZHANG, Zhiqiang KU, Chengcheng ZHANG, Xiaoye LIU, Heyu CHEN, JingJing XIE, Maria Jose COSTA, An SONG, X. Charlene LIAO
Life of this patent
Estimating the term…
Abstract
Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.
Claims21
1-59. (canceled)
An isolated monoclonal antibody or an antigen-binding fragment thereof that binds to LILRB2 comprising a heavy chain (HC) variable region (VH) and a light chain (LC) variable region (VL) comprising heavy chain complementarity determining regions 1-3 (HCDR1-3) and light chain complementarity determining regions 1-3 (LCDR1-3) as set out below:
- HCDR1 comprising SEQ ID NO:
- 121,
- HCDR2 comprising SEQ ID NO:
- 122,
- HCDR3 comprising SEQ ID NO:
- 123,
- LCDR1 comprising SEQ ID NO:
- 124,
- LCDR2 comprising SEQ ID NO:
- 125, and
- LCDR3 comprising SEQ ID NO:
- 126.
Dependencies are inferred from the claim text.